This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech Stock Mailbag: AVI, Aveo, Spectrum

BOSTON ( TheStreet) -- Renton L. opens this week's Biotech Stock Mailbag: "Was there anything noteworthy in the AVI BioPharma (AVII) update announced this week? Are you still optimistic about this drug's chances; maybe the market is getting this drug all wrong?"

AVI's eteplirsen is the first drug ever to significantly increase the production of dystrophin in boys with Duchenne muscular dystrophy (DMD). That's pretty darn remarkable, so yes, I believe there is reason for optimism.

The problem is that eteplirsen's ability to generate dystrophin has not yet translated into a meaningful clinical benefit for DMD patients. AVI presented new data this week showing small improvements in walking ability in some patients. The data were highly variable, however: Two patients with increased dystrophin production actually performed significantly worse on a six-minute walk test.

The riddle AVI needs to solve is how to bridge the gap between new dystrophin production and demonstrating a clinical benefit for patients. Six-minute walk tests are notorious for producing confounding results, so maybe an alternative measure needs to be used. Or perhaps the increase in dystrophin levels that eteplirsen is able to produce is just not robust enough to improve the outlook for DMD patients.

What AVI has demonstrated with eteplirsen is very important but more is needed and risks remain. I think that fairly explains why AVI shares sold off after the eteplirsen data were announced earlier this month.

AVI's tenuous cash position doesn't help matters. This is a company in desperate need of a partner.

Two emails on Aveo Pharmaceuticals (AVEO): Nico asks, "What in the world is going on with AVEO? Is there anything new driving the stock down? Do you expect a run into ASCO?"

Jay R. writes, "Would you mind weighing in on Aveo ahead of ASCO? When the data were released, analysts were disappointed by the margin of benefit for tivozanib versus sorafenib. In early February, Aveo CFO David Johnston held a meeting with RBC Capital. Johnston cited an advisory board that was held with 16 kidney cancer KOLs Key Opinion Leaders. According to Johnston, each KOL arrived at the meeting with a similar skepticism about the impact of the data relative to the other competitors. Following a confidentiality agreement and a view of both efficacy and safety data, the experts provided feedback. Based on their review, the experts agreed that tivozanib is among the most effective agents in kidney cancer and clearly the best efficacy and by far the best safety."

1 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,172.68 -107.06 -0.62%
S&P 500 1,994.29 -16.11 -0.80%
NASDAQ 4,527.6890 -52.10 -1.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs